Aural Analytics Speech Platform Powers Clinical Trial Showing Potential Early Treatment Effect for ALS Patients Treated with Investigational Therapy | Business Wire

A Phase 2 clinical trial in ALS patients found that use of reldesemtiv, designed to ease muscle contraction with minimal nerve stimulation, led to a slower decline in speech motor control relative to placebo. Speech data for the study was collected using Aural Analytics’ speech analytics platform technology. Click here to learn more